Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL14633570

Cc1cc(Nc2nccc(N(C)c3n[nH]c4cc(F)c(C)cc34)n2)cc(S(C)(=O)=O)c1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 3/20 0.43
KDR P35968 8/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PAK1 Q13153 1/20 0.39
SYK P43405 5/20 0.39
KIT P10721 1/20 0.37
PDGFRA P16234 1/20 0.37
RIPK1 Q13546 2/20 0.37
MLKL Q8NB16 2/20 0.37
RIPK3 Q9Y572 2/20 0.37
ABCB11 O95342 1/20 0.37
AURKA O14965 1/20 0.36
PARP1 P09874 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14633630 0.91 EPHB4 (0.48) EPHB4KDRCYP3A4CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL14634065 0.91 EPHB4 (0.47) EPHB4KDRCYP3A4CYP2D6CYP2C9
SCHEMBL2515028 0.89 EPHB4 (0.49) EPHB4KDRCYP3A4CYP2D6CYP2C9
SCHEMBL2435385 0.85 KDR (0.49) EPHB4KDRCYP3A4CYP2D6CYP2C9
SCHEMBL14633711 0.83 EPHB4 (0.50) EPHB4KDRCYP3A4CYP2D6CYP2C9
SCHEMBL2435394 0.82 KDR (0.49) EPHB4KDRCYP3A4CYP2D6CYP2C9
SCHEMBL14634115 0.82 EPHB4 (0.54) EPHB4KDRCYP3A4CYP2D6CYP2C9
SCHEMBL14634103 0.82 EPHB4 (0.46) EPHB4KDRCYP3A4CYP2D6CYP2C9
SCHEMBL2436250 0.81 EPHB4 (0.46) EPHB4KDRCYP3A4CYP2D6CYP2C9
Trifluoroacetic Acid SCHEMBL14633981 0.81 EPHB4 (0.57) EPHB4KDRCYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 EPHB4 2462/4885KDR 541/4885CYP3A4 3598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.